CA2397016A1 — Use of lipid conjugates in the treatment of disease
Assigned to Yissum Research Development Co of Hebrew University of Jerusalem · Expires 2001-07-19 · 25y expired
What this patent protects
The invention provides a compound according to the formula: (see formula I) wherein R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alky…
USPTO Abstract
The invention provides a compound according to the formula: (see formula I) wherein R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, wherein said spacer comprises -CO-alkylene-NH-, -CO-alkylene-CO- or a combination thereof; X is either a physiologically acceptable monomer, dimer, or oligomer wherein X is a glycosaminoglycan; and n is a number from 1 to 1,000.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.